Glysantis is pleased to announce the appointment of Dr. Jondavid (Jd) de Jong, as Manager R&D. “Glysantis’ R&D portfolio has been growing rapidly and we needed focused management attention on our suite of projects,” says Phil Whiting, CEO of Glysantis. “Jd’s new role will help us maintain laser focus on bringing novel therapeutic applications of our unique nanomaterial quickly to the market. We can expect to see some exciting announcements from this program over the next few years under his leadership.”
Jd has a Ph.D. in Molecular Virology from University of Guelph and has over 15 years of experience in molecular biology and virology research.
Glysantis Inc. is a Canadian biotech company with a commitment to the development of biomedical applications of our novel platform nanomaterial NanoDendrix®. Our pipeline includes vaccine biomanufacturing, anti-infectives, immunomodulation and targeted drug delivery.